Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042941 | 0.88 | CHRM2 (0.65) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL12787585 | 0.88 | CHRM2 (0.65) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1039704 | 0.88 | CHRM2 (0.65) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1043555 | 0.81 | CHRM2 (1.00) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL17147302 | 0.80 | CHRM2 (0.78) | CHRM2CHRM3ADRA1AADRA1B | |
| Bromide SCHEMBL6649504 | 0.80 | CHRM2 (0.97) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL12787584 | 0.79 | CHRM2 (0.71) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| Bromide SCHEMBL194843 | 0.79 | CHRM2 (0.93) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1044113 | 0.79 | CHRM2 (0.71) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1043522 | 0.79 | CHRM2 (0.71) | CHRM2CHRM3ADRA1AADRA1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160310503-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160310503-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310503-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885PIK3CD 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.